Affimed(AFMD) GlobeNewswire News Room·2024-11-14 11:30Core Insights - Affimed N.V. reported financial results and clinical updates for Q3 2024, highlighting progress in its immuno-oncology pipeline and financial position [2][3]. Clinical Updates - The AFM24 trial for non-small cell lung cancer (NSCLC) EGFR wild-type cohort has completed enrollment, with objective response rate (ORR) and safety data to be presented on December 17, 2024. Previous data showed a 71% disease control rate among patients who failed chemotherapy and PD-1/PD-L1 treatment [4][7]. - Updated clinical data for Acimtamig (AFM13) in combination with AlloNK® will be presented at ASH 2024, with a reported ORR of 83.3% and a complete response rate (CRR) of 50% in advanced Hodgkin Lymphoma patients [5][7]. - The AFM28 monotherapy phase 1 dose-escalation study will present updated clinical data at ASH 2024, with initial results showing a composite complete remission (CRc) rate of 50% in relapsed/refractory acute myeloid leukemia (AML) patients [6][7]. Financial Highlights - As of September 30, 2024, the company had cash, cash equivalents, and short-term investments totaling €24.1 million, projected to last into Q4 2025 based on current operating plans [9][10]. - Total revenue for Q3 2024 was €0.2 million, a significant decrease from €2.0 million in Q3 2023, primarily due to the completion of prior collaborations [11]. - Research and development expenses decreased to €10.1 million in Q3 2024 from €21.5 million in the same quarter of 2023, attributed to reduced clinical trial costs and restructuring [12]. - The net loss for Q3 2024 was €15.1 million, or €0.94 loss per share, compared to a net loss of €24.4 million, or €1.63 loss per share, in Q3 2023 [14].